帕金森病患者血清miR-214-3p、miR-124-3p表达水平与病情严重程度的关系及其早期诊断价值

doi:10.11958/20250429

天津医药 ›› 2025, Vol. 53 ›› Issue (5): 498-502.doi: 10.11958/20250429

帕金森病患者血清miR-214-3p、miR-124-3p表达水平与病情严重程度的关系及其早期诊断价值

周美娟¹(), 缪小祥²^,^△()

1 如皋市中医院急诊内科（邮编226500）
2 脑病科

收稿日期:2025-02-07 修回日期:2025-03-07 出版日期:2025-05-15 发布日期:2025-05-28
通讯作者: △ E-mail:390438807@qq.com
作者简介:周美娟（1985），女，副主任中医师，主要从事急诊科常见病及中西医结合治疗心血管疾病方面研究。E-mail:nj5836@sina.com
基金资助:
南通市卫生健康委员会科研课题专项(MSZ2024096)

Relationship between serum expression levels of miR-214-3p and miR-124-3p and the severity of disease in patients with Parkinson's disease and their values in early diagnosis

ZHOU Meijuan¹(), MIAO Xiaoxiang²^,^△()

1 Department of Emergency Internal Medicine
2 Department of Neurology, Rugao Traditional Chinese Medicine Hospital, Rugao 226500, China

Received:2025-02-07 Revised:2025-03-07 Published:2025-05-15 Online:2025-05-28
Contact: △ E-mail:390438807@qq.com

周美娟, 缪小祥. 帕金森病患者血清miR-214-3p、miR-124-3p表达水平与病情严重程度的关系及其早期诊断价值[J]. 天津医药, 2025, 53(5): 498-502.

ZHOU Meijuan, MIAO Xiaoxiang. Relationship between serum expression levels of miR-214-3p and miR-124-3p and the severity of disease in patients with Parkinson's disease and their values in early diagnosis[J]. Tianjin Medical Journal, 2025, 53(5): 498-502.

摘要/Abstract

摘要：

目的分析血清微小RNA（miR）-214-3p、miR-124-3p表达水平与帕金森病（PD）患者病情严重程度的关系及早期诊断价值。方法选取96例PD患者为PD组，另选取同期106例健康者为对照组。依据96例患者严重程度分为早期组（Ⅰ—Ⅱ期，n=59）和中晚期组（Ⅲ—Ⅴ期，n=37）。RT-qPCR检测血清miR-214-3p和miR-124-3p水平；相关性分析采用Spearman法；采用多因素Logistic回归分析PD严重程度的影响因素；血清miR-214-3p、miR-124-3p诊断PD及其严重程度的效能采用受试者工作特征（ROC）曲线分析。结果相比对照组，PD组血清miR-214-3p、miR-124-3p水平较低（P<0.05）。相比早期组，中晚期组病程较长、同型半胱氨酸（Hcy）水平较高（P<0.05），血清miR-214-3p、miR-124-3p水平较低（P<0.05）。Spearman分析显示，PD患者血清miR-214-3p、miR-124-3p与Hoehn-Yahr分期呈负相关（P<0.05）。多因素Logistic回归显示，病程（OR=1.249）、Hcy（OR=1.156）、血清miR-214-3p（OR=0.925）、miR-124-3p（OR=0.917）均为PD严重程度的影响因素（P<0.05）。ROC曲线分析显示，血清miR-214-3p、miR-124-3p联合诊断PD的敏感度为85.42%，特异度为81.90%；血清miR-214-3p、miR-124-3p联合诊断中晚期PD的敏感度为89.16%，特异度为79.66%。结论 PD患者血清miR-214-3p、miR-124-3p水平较低，且二者水平与其严重程度有关。检测血清miR-214-3p、miR-124-3p有助于PD的诊断及病情评估。

关键词: 帕金森病, 微RNAs, ROC曲线, 严重程度, miR-214-3p, miR-124-3p

Abstract:

Objective To analyze the relationship between the expression levels of serum microRNA-214-3p and miR-124-3p with the severity of Parkinson's disease (PD), and their early diagnostic value. Methods From January 2018 to December 2023, 96 PD patients admitted to Rugao Traditional Chinese Medicine Hospital were selected as the PD group, and 106 healthy individuals were selected as the control group. According to the severity of 96 patients, they were grouped into the early stage group (I-II stage, n=59）and the mid to late stage group (III-V stage, n=37). RT-qPCR was applied to detect serum levels of miR-214-3p and miR-124-3p. Spearman method was used for correlation analysis. The influencing factors of PD severity were analyzed using multiple Logistic regression analysis. The efficacy of serum miR-214-3p and miR-124-3p in diagnosing PD and its severity was analyzed by receiver operating characteristics (ROC). Results Compared with the control group, the serum levels of miR-214-3p and miR-124-3p were lower in the PD group (P<0.05). Compared with the early stage group, there were a longer disease course, higher level of homocysteine (Hcy) and lower levels of serum miR-214-3p and miR-124-3p in the mid to late stage group (P<0.05). Spearman analysis showed that serum miR-214-3p and miR-124-3p were negatively correlated with Hoehn-Yahr staging in PD patients (P<0.05). Multivariate Logistic regression showed that disease duration (OR=1.249), Hcy (OR=1.156), serum miR-214-3p (OR=0.925) and miR-124-3p (OR=0.917) were factors influencing the severity of PD (P<0.05). ROC analysis showed that the sensitivity and specificity of serum miR-214-3p and miR-124-3p combined in the diagnosis of PD were 85.42% and 81.90% respectively. The sensitivity and specificity of serum miR-214-3p and miR-124-3p in the diagnosis of advanced PD were 89.16% and 79.66% respectively. Conclusion The serum levels of miR-214-3p and miR-124-3p are relatively low in PD patients, and their levels are related to the severity of disease. The detection of serum miR-214-3p and miR-124-3p is helpful for the diagnosis and evaluation of PD.

Key words: Parkinson disease, microRNAs, ROC curve, severity, miR-214-3p, miR-124-3p

中图分类号:

R742.5

图/表 8

参考文献 22

[1]	KUMAR S, GOYAL L, SINGH S. Tremor and rigidity in patients with Parkinson's disease:emphasis on epidemiology,pathophysiology and contributing factors[J]. CNS Neurol Disord Drug Targets, 2022, 21(7):596-609. doi:10.2174/1871527320666211006142100.
[2]	翟书鹏, 贾航, 苗统, 等. 帕金森病患者血清Trx1、PDCD4、AQP4水平与认知功能的关系[J]. 天津医药, 2025, 53(2):146-150.
	ZHAI S P, JIA H, MIAO T, et al. The relationship between serum Trx1,PDCD4,AQP4 expression and cognitive function in patients with Parkinson's disease[J]. Tianjin Med J, 2025, 53(2):146-150. doi:10.11958/20241632.
[3]	RODRIGUES-COSTA M, FERNANDES M S S, JUREMA-SANTOS G C, et al. Nutrigenomics in Parkinson's disease:diversity of modulatory actions of polyphenols on epigenetic effects induced by toxins[J]. Nutr Neurosci, 2023, 26(1):72-84. doi:10.1080/1028415X.2021.2017662.
[4]	WALKER L, ATTEMS J. Prevalence of concomitant pathologies in Parkinson's disease:implications for prognosis,diagnosis,and insights into common pathogenic mechanisms[J]. J Parkinsons Dis, 2024, 14(1):35-52. doi:10.3233/JPD-230154.
[5]	SALEEM A, JAVED M, AKHTAR M F, et al. Current updates on the role of microRNA in the diagnosis and treatment of neurodegenerative diseases[J]. Curr Gene The, 2024, 24(2):122-134. doi:10.2174/0115665232261931231006103234.
[6]	LI L, WANG H, LI H, et al. Long noncoding RNA BACE1-antisense transcript plays a critical role in Parkinson's disease via microRNA-214-3p/Cell death-inducing p53-target protein 1 axis[J]. Bioengineered, 2022, 13(4):10889-10901. doi:10.1080/21655979.2022.2066750.
[7]	ESTEVES M, CRISTOVAO A C, VALE A, et al. MicroRNA-124-3p modulates alpha-synuclein expression levels in a paraquat-induced in vivo model for Parkinson's disease[J]. Neurochem Res, 2024, 49(7):1677-1686. doi:10.1007/s11064-024-04130-y.
[8]	中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4):268-271.
	Parkinson's Disease and Movement Disorders Group,Chinese Society of Neurology. Diagnostic criteria for Parkinson's disease in China(2016 edition)[J]. Chinese Journal of Neurology, 2016, 49(4):268-271. doi:10.3760/cma.j.issn.1006-7876.2016.04.002.
[9]	KATAOKA H, SUGIE K. Association between fatigue and Hoehn-Yahr staging in Parkinson's disease:eightyear follow-up study[J]. Neurol Int, 2021, 13(2):224231-224240. doi:10.3390/neurolint13020023.
[10]	ZHENG Z, ZHU Z, ZHOU C, et al. Burden of Parkinson disease in China,1990-2019:findings from the 2019 global burden of disease study[J]. Neuroepidemiology, 2023, 57(1):51-64. doi:10.1159/000527372.
[11]	KHAN M A, HAIDER N, SINGH T, et al. Promising biomarkers and therapeutic targets for the management of Parkinson's disease:recent advancements and contemporary research[J]. Metab Brain Dis, 2023, 38(3):873-919. doi:10.1007/s11011-023-01180-z.
[12]	LIU J, ZHANG H, DI K, et al. Circular noncoding RNA circ-0007865,serves as a competing endogenous RNA,targeting the miR-214-3p/FKBP5 axis to regulate oxygen-glucose deprivation-induced injury in brain microvascular endothelial cells[J]. Neuroreport, 2022, 33(4):163-172. doi:10.1097/WNR.00000000000001751.
[13]	燕佳辉. miR-214-3p调控ATG3影响多巴胺能神经元功能参与PD发病机制的研究[D]. 郑州: 郑州大学, 2022.
	YAN J H. miR-214-3p regulates ATG3,affects dopaminergic neuron function and participates in the pathogenesis of PD[D]. Zhengzhou: Zhengzhou University, 2022. doi:10.27466/d.cnki.gzzdu.2022.000765.
[14]	杜姝, 傅增辉, 姜岩, 等. 基于Fas/FasL信号通路探究调控miR-214-3p对帕金森病大鼠的干预效果[J]. 中国老年学杂志, 2023, 43(17):4290-4294.
	DU S, FU Z H, JIANG Y, et al. To explore the intervention effect of regulating miR-214-3p on Parkinson's disease rats based on Fas/FasL signaling pathway[J]. Chinese Journal of Gerontology, 2023, 43(17):4290-4294. doi:10.3969/j.issn.1005-9202.2023.17.052.
[15]	LIAO Y, GU Y, WANG J, et al. HSF1 inhibits microglia activation to attenuate neuroinflammation via regulating miR-214-3p and NFATc2 in Parkinson's disease[J]. Folia Neuropathol, 2023, 61(1):53-67. doi:10.5114/fn.2022.122800.
[16]	李彦霖, 王有民, 朱莉. miR-124在常见神经退行性疾病中的作用[J]. 南京医科大学学报(自然科学版), 2024, 44(1):123-129.
	LI Y L, WANG Y M, ZHU L. Roles of miR-124 in neurodegenerative diseases[J]. Journal of Nanjing Medicial University(Natural Sciences), 2024, 44(1):123-129. doi:10.7655/NYDXBNSN230703.
[17]	WANG Y, LI D, ZHANG L, et al. Exosomes derived from microglia overexpressing miR-124-3p alleviate neuronal endoplasmic reticulum stress damage after repetitive mild traumatic brain injury[J]. Neural Regen Res, 2024, 19(9):2010-2018. doi:10.4103/1673-5374.391189.
[18]	罗丹, 吴继祥, 覃国勇, 等. 帕金森病患者血清miR-124水平与认知损害、炎症及氧化应激反应的相关性[J]. 国际检验医学杂志, 2022, 43(18):2249-2254.
	LUO D, WU J X, QIN G Y, et al. Correlation of serum miR-124 level with cognitive impairment and inflammatory oxidative stress response in patients with Parkinson's disease[J]. International Journal of Laboratory Medicine, 2022, 43(18):2249-2254. doi:10.3969/j.issn.1673-4130.2022.18.015.
[19]	ZHANG Y J, ZHU W K, QI F Y, et al. CircHIPK3 promotes neuroinflammation through regulation of the miR-124-3p/STAT3/NLRP3 signaling pathway in Parkinson's disease[J]. Adv Clin Exp Med, 2023, 32(3):315-329. doi:10.17219/acem/154658.
[20]	FAN J, WU D, GUO Y, et al. SOS1-IT1 silencing alleviates MPP+-induced neuronal cell injury through regulating the miR-124-3p/PTEN/AKT/mTOR pathway[J]. J Clin Neurosci, 2022, 99(1):137-146. doi:10.1016/j.jocn.2022.01.003.
[21]	PHOKAEWVARANGKUL O, BHIDAYASIRI R, GARCIA-RUIZ P, et al. Homocysteine,vitamin B metabolites,dopamine-substituting compounds,and symptomatology in Parkinson's disease:clinical and therapeutic considerations[J]. J Neural Transm(Vienna), 2023, 130(11):1451-1462. doi:10.1007/s00702-023-02684-9.
[22]	黄琦, 沈慧, 李文, 等. 帕金森病病人血清25-羟维生素D、Hcy水平与运动、非运动症状的相关性分析[J]. 中西医结合心脑血管病杂志, 2024, 22(5):938-941.
	HUANG Q, SHEN H, LI W, et al. Correlation analysis of serum 25-hydroxyvitamin D and Hcy levels with motor and non-motor symptoms in patients with Parkinson's disease[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2024, 22(5):938-941. doi:10.12102/j.issn.1672-1349.2024.05.033.

组别	n	miR-214-3p	miR-124-3p
对照组	106	0.98±0.19	1.01±0.20
PD组	96	0.74±0.14	0.82±0.16
t		10.130^＊＊	7.406^＊＊

组别	n	miR-214-3p	miR-124-3p
对照组	106	0.98±0.19	1.01±0.20
PD组	96	0.74±0.14	0.82±0.16
t		10.130^＊＊	7.406^＊＊

组别	n		性别						年龄/岁		体质量指数/（kg/m²）				受教育程度							吸烟史			饮酒史
组别	n		男			女			年龄/岁		体质量指数/（kg/m²）				初中及以下		高中/中专			专科及以上		吸烟史			饮酒史
早期组	59		26（44.07）			33（55.93）			68.53±7.05		22.76±2.31				20（33.90）		27（45.76）			12（20.34）		21（35.59）			18（30.51）
中晚期组	37		19（51.35）			18（48.65）			69.65±7.18		23.07±2.38				18（48.65）		13（35.14）			6（16.22）		17（45.95）			15（40.54）
t或χ²			0.484						0.752		0.633				2.072							1.014			1.014
组别		糖尿病史			高血压史			高脂血症史				临床分型							起病侧
组别		糖尿病史			高血压史			高脂血症史				震颤型	强直型			混合型			左侧		右侧			双侧
早期组		9（15.25）			24（40.68）			15（25.42）				19（32.20）	14（23.73）			26（44.07）			19（32.20）		25（42.37）			15（25.42）
中晚期组		10（27.03）			17（45.95）			13（35.14）				13（35.14）	10（27.03）			14（37.84）			9（4.32）		15（40.54）			13（35.14）
χ²		1.985			0.258			1.038				0.369							1.238
组别				病程/月			TG/（mmol/L）			TC/（mmol/L）				LDL-C/（mmol/L）				HDL-C/（mmol/L）					Hcy/（μmol/L）
早期组				26.49±5.37			1.27±0.24			4.52±0.61				1.76±0.38				1.13±0.25					16.37±3.86
中晚期组				37.81±7.21			1.33±0.29			4.59±0.65				1.82±0.43				1.04±0.21					21.05±4.63
t				8.791^＊＊			1.099			0.534				0.716				1.823					5.350^＊＊

组别	n		性别						年龄/岁		体质量指数/（kg/m²）				受教育程度							吸烟史			饮酒史
组别	n		男			女			年龄/岁		体质量指数/（kg/m²）				初中及以下		高中/中专			专科及以上		吸烟史			饮酒史
早期组	59		26（44.07）			33（55.93）			68.53±7.05		22.76±2.31				20（33.90）		27（45.76）			12（20.34）		21（35.59）			18（30.51）
中晚期组	37		19（51.35）			18（48.65）			69.65±7.18		23.07±2.38				18（48.65）		13（35.14）			6（16.22）		17（45.95）			15（40.54）
t或χ²			0.484						0.752		0.633				2.072							1.014			1.014
组别		糖尿病史			高血压史			高脂血症史				临床分型							起病侧
组别		糖尿病史			高血压史			高脂血症史				震颤型	强直型			混合型			左侧		右侧			双侧
早期组		9（15.25）			24（40.68）			15（25.42）				19（32.20）	14（23.73）			26（44.07）			19（32.20）		25（42.37）			15（25.42）
中晚期组		10（27.03）			17（45.95）			13（35.14）				13（35.14）	10（27.03）			14（37.84）			9（4.32）		15（40.54）			13（35.14）
χ²		1.985			0.258			1.038				0.369							1.238
组别				病程/月			TG/（mmol/L）			TC/（mmol/L）				LDL-C/（mmol/L）				HDL-C/（mmol/L）					Hcy/（μmol/L）
早期组				26.49±5.37			1.27±0.24			4.52±0.61				1.76±0.38				1.13±0.25					16.37±3.86
中晚期组				37.81±7.21			1.33±0.29			4.59±0.65				1.82±0.43				1.04±0.21					21.05±4.63
t				8.791^＊＊			1.099			0.534				0.716				1.823					5.350^＊＊

组别	n	miR-214-3p	miR-124-3p
早期组	59	0.81±0.15	0.89±0.17
中晚期组	37	0.63±0.12	0.72±0.14
t		6.163^＊＊	5.093^＊＊

帕金森病患者血清miR-214-3p、miR-124-3p表达水平与病情严重程度的关系及其早期诊断价值

Relationship between serum expression levels of miR-214-3p and miR-124-3p and the severity of disease in patients with Parkinson's disease and their values in early diagnosis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 8

参考文献 22

相关文章 15

编辑推荐

Metrics

本文评价

变量	β	SE	Wald χ²	P	OR	OR 95%CI
病程	0.222	0.072	9.536	0.002	1.249	1.085~1.438
Hcy	0.145	0.060	5.838	0.016	1.156	1.028~1.300
血清miR-214-3p	-0.078	0.031	6.325	0.011	0.925	0.825~0.983
血清miR-124-3p	-0.087	0.036	5.793	0.016	0.917	0.854~0.984
常数项	-0.173	0.054	20.062	0.001	0.023

变量	AUC	95%CI	截断值	敏感度/ %	特异度/ %	约登指数
血清miR-214-3p	0.742	0.676~0.801	0.88	66.67	83.96	0.506
血清miR-124-3p	0.785	0.722~0.840	0.89	70.83	83.81	0.546
联合诊断	0.891	0.840~0.931	-	85.42	81.90	0.673

变量	AUC	95%CI	截断值	敏感度/ %	特异度/ %	约登指数
血清miR-214-3p	0.806	0.713~0.880	0.69	70.27	83.05	0.533
血清miR-124-3p	0.823	0.732~0.893	0.83	72.97	81.36	0.543
联合诊断	0.900	0.822~0.952	-	89.19	79.66	0.689

[1]	王欣欣, 许慧, 吴晓. 妊娠期肝内胆汁淤积症合并GDM孕妇不良妊娠结局的影响因素及预测模型构建[J]. 天津医药, 2025, 53(5): 503-508.
[2]	胡卓, 谢松波, 游诗伟. 序贯器官衰竭评分联合Clara细胞蛋白和血管生成素-2对脓毒症所致ARDS的预测价值[J]. 天津医药, 2025, 53(5): 519-522.
[3]	宋志新, 叶建军, 杨道武. 交通创伤患者继发创伤性凝血功能障碍的危险因素分析[J]. 天津医药, 2025, 53(4): 416-419.
[4]	翟书鹏, 贾航, 苗统, 魏康康, 周国平. 帕金森病患者血清Trx1、PDCD4、AQP4水平与认知功能的关系[J]. 天津医药, 2025, 53(2): 146-150.
[5]	张小庆, 赵慧霞, 曹鄂洪, 张连霞, 宫秀娟. PIV、HCAR、PCT/PLT在老年COPD肺部感染中的应用价值[J]. 天津医药, 2025, 53(2): 170-175.
[6]	吴静静, 张福森, 陈皓, 赵亿, 刘泉, 李冬梅. 血清Syndecan-1、endocan-1联合qSOFA评分在脓毒症诊断及预后评估中的应用价值[J]. 天津医药, 2025, 53(2): 185-188.
[7]	蒋晓涵, 曹杰, 刘丹丹, 薛丹, 郭志国. aMAP评分联合RAR及PIV构建慢性肝病患者肝细胞癌发生风险的预测模型[J]. 天津医药, 2025, 53(1): 42-46.
[8]	焦爱菊, 任宝龙, 张春花, 李文瑞, 赵玮婧. NIHSS评分联合血清BDNF、IL-6对脑卒中后抑郁的预测价值[J]. 天津医药, 2024, 52(9): 963-966.
[9]	肖小丽, 谢瑶, 龙志. 丙型肝炎患者血清miR-155、miR-205-5p水平变化及诊断价值[J]. 天津医药, 2024, 52(9): 967-970.
[10]	李勇, 苏亚坤, 张宏博, 李原, 李占虎, 闫小菊. 原发性高血压早期肾损害患者血清白脂素水平的临床意义[J]. 天津医药, 2024, 52(6): 609-613.
[11]	缪春波, 许迎春, 常以芳. 根皮苷通过下调miR-125a-5p减轻缺氧/复氧诱导的H9C2细胞氧化应激和凋亡[J]. 天津医药, 2024, 52(12): 1233-1238.
[12]	孙瑞雪, 刘霄霄, 岳欣怡, 杨冬梅, 任鲁宁, 王菲, 杜红阳. 术前血液学炎症指标对基底细胞癌复发风险的预测价值[J]. 天津医药, 2024, 52(12): 1274-1277.
[13]	顾芸芸, 仲崇明, 杨海燕. 尿酸/白蛋白比值对慢性肾脏病患者并发冠心病的预测价值[J]. 天津医药, 2024, 52(11): 1202-1206.
[14]	吴美娜, 戴为正, 潘毓敦, 傅懋林, 陈晓瑜. 常规脑电图联合血清miR-146a、miR-129-5p水平检测对药物难治性癫痫的临床诊断价值[J]. 天津医药, 2024, 52(11): 1207-1210.
[15]	宫秀娟, 赵慧霞, 张小庆, 张连霞. 重症社区获得性肺炎患者PIV、IL-6、HBP、PAB水平对疗效的评估价值[J]. 天津医药, 2024, 52(11): 1216-1220.